文献速递甲状腺与颈部外科

机器人甲状腺切除术与开放甲状腺切除术治疗甲状腺癌的系统评价与荟萃分析

Robotic thyroidectomy versus conventional open thyroidectomy for thyroid cancer: a systematic review and meta-analysis.
PubMed 文献 · Surg Endosc · 2017-03-23

RT的不良事件与并发症发生率及手术完整性指标与OT相当,且出血量更少、吞咽障碍更轻、美容满意度更好,但淋巴结清扫数目较少、手术时间更长、总引流量更多、术后血清Tg水平更高。结论认为RT与OT同样安全,但仍需随机临床试验和更大样本长期随访进一步验证。

要点

  • RT与OT在暂时性/永久性低钙血症、喉返神经麻痹等并发症及手术完整性指标上相当。
  • RT出血量更少、吞咽障碍更轻、美容满意度更高,但清扫淋巴结数目较少。
  • OT手术时间更短、总引流量更少、术后血清Tg水平更低。

核心结论

  • RT治疗甲状腺癌与OT同样安全,不良事件、并发症及复发率与OT相当。
  • RT出血量更少、清扫淋巴结数目较少、吞咽障碍更轻、美容满意度更好。
  • OT手术时间更短、总引流量更少、术后血清Tg水平更低。
  • 仍需随机临床试验和更大样本长期随访进一步验证机器人入路的价值。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed、MEDLINE、EMBASE、Cochrane Library、Web of Science及ClinicalTrials.gov至2016年7月。

主要发现

  • RT与OT的不良事件和并发症发生率相当,包括暂时性/永久性低钙血症、暂时性声音嘶哑、永久性喉返神经麻痹、暂时性/永久性甲状旁腺功能减退、血肿、术后出血、血清肿、乳糜漏及VHI-10评分。
  • RT与OT的手术完整性相当,包括术后放射性碘(RAI)消融率、RAI消融次数、平均总RAI消融剂量、术后RAI刺激后Tg均值及首次消融后刺激后Tg<1.0 ng/ml的比例。
  • RT出血量更少(WMD -1.47,p=0.04),清扫淋巴结数目较少(WMD -1.21,p=0.0002),吞咽障碍更轻(WMD -4.17,p<0.00001),美容满意度更好(OR 4.05,p<0.00001)。
  • OT手术时间更短(WMD 69.80,p<0.00001),总引流量更少(WMD 66.53,p<0.0001),术后血清Tg水平更低(WMD 0.21,p<0.00001)。

临床怎么用

  • 对于关注美容效果和吞咽功能的甲状腺癌患者,RT可作为与OT同样安全的选择。
  • 选择RT时需权衡其清扫淋巴结数目较少及术后血清Tg水平较高的潜在肿瘤学影响。
  • OT在手术时间、引流量和术后Tg水平方面具有优势,仍是常规选择。

局限性

  • 结论基于截至2016年7月的文献,需随机临床试验和更大样本长期随访进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the new technical alternative offered by the robotic surgery for minimally invasive thyroid surgery, the role of the robotic thyroidectomy (RT) in thyroid cancer has been highly disputed. This paper gives a systematic review and meta-analysis aiming to compare RT and open thyroidectomy (OT) based on the surgical outcomes and oncologic results. METHODS: Relevant literature was searched from various databases up to July 2016, including PubMed, MEDLINE, EMBASE, Cochrane Library, Web of science and Clinical Trials. gov. Outcomes of interest included patient characteristics, surgical outcomes, adverse events and complications, recurrence rate, and surgical completeness. RESULTS: The systematic review and meta-analysis were based on the 5200 cases selected from the twenty-three publications. RT was associated with an equivalent adverse event and complication rate including transient hypocalcemia, permanent hypocalcemia, transient hoarseness, permanent recurrent laryngeal nerve (RLN) palsy, transient hypoparathyroidism, permanent hypoparathyroidism, hematoma, postoperative bleeding, seroma, chyle leakage, the Voice Handicap Index-10 (VHI-10) score, as well as equivalent surgical completeness including postoperative radioactive iodine (RAI) ablation rate, number of RAI ablation sessions, mean total RAI ablation dose, mean stimulated Tg of postoperation RAI, and proportion of stimulated Tg < 1.0 ng/ml on first ablation. Moreover, RT had lesser blood loss (WMD - 1.47, p = 0.04), smaller number of retrieved lymph nodes (WMD - 1.21, p = 0.0002), a low level of swallowing impairment (WMD - 4.17, p < 0.00001), and better cosmetic satisfaction (OR 4.05, p < 0.00001). However, OT was associated with shorter operation time (WMD 69.80, p < 0.00001), less total drain amount (WMD 66.53, p < 0.0001), and lower postoperative serum Tg level (WMD 0.21, p < 0.00001). CONCLUSIONS: RT is as safe as OT for the treatment of thyroid cancer. Based on the long-time follow-up and surgical completeness, the adverse events and complications, and recurrence rate of RT were comparable with OT. RT was associated with a significantly lesser blood loss, smaller number of retrieved lymph nodes, a lower level of swallowing impairment, and better cosmetic satisfaction. In contrast, OT was associated with shorter operation time, smaller total drain amount, and lower postoperative serum Tg level. Overall, randomized clinical trials and larger patient cohort with long-term follow-up are still essential to further demonstrate the value of the robotic approach.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Pan JH, Zhou H, Zhao XX, et al. Robotic thyroidectomy versus conventional open thyroidectomy for thyroid cancer: a systematic review and meta-analysis. Surg Endosc. 2017. PMID: 28337546. doi:10.1007/s00464-017-5433-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。